日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Linavonkibart 和 pembrolizumab 治疗免疫检查点阻断耐药的晚期实体瘤:一项 1 期试验。

Yap Timothy A, Sweis Randy F, Vaishampayan Ulka, Kilari Deepak, Gainor Justin F, McKean Meredith, Barve Minal, Tarhini Ahmad A, Bockorny Bruno, Sonpavde Guru, Park David, Babu Sunil, Ju Yawen, Liu Lan, Henry Susan, Tirucherai Giridhar S, DeWall Stephen, Qatanani Mohammed, Marantz Jing L, Gan Lu

Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA Targeted Tubulysin Conjugate EC1169

在PSMA靶向Tubulysin缀合物EC1169的I期研究中,对CTC上PSMA表达进行相关性生物标志物分析和PSMA成像

Zaidi, Samir; Kuo, Phillip H; Paiva Prudente, Tiago; Lacuna, Kristine P; Babiker, Hani M; Aparicio, Renan; Schonhoft, Joseph D; Fernandez, Luisa; Messmann, Richard; Groaning, Michael; Tolcher, Anthony W; Gordon, Michael S; Yoo, Don C; Vaishampayan, Ulka; Picus, Joel; Petrylak, Daniel P; Sartor, Oliver; Morris, Michael J

Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 study

在EV-302研究中评估恩福妥单抗联合帕博利珠单抗与铂类化疗治疗晚期尿路上皮癌患者的患者报告结局(PRO)。

Okobi, Tobechukwu J; Vaishampayan, Neil; Subramanya, Deepthi; Tagawa, Scott T

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

COSMIC-021 Ib期研究:卡博替尼联合阿特珠单抗治疗局部晚期或转移性尿路上皮癌队列的结果

Pal, Sumanta K; Loriot, Yohann; Necchi, Andrea; Singh, Parminder; Castellano, Daniel; Pagliaro, Lance; Suarez, Cristina; McGregor, Bradley A; Vaishampayan, Ulka N; Hauke, Ralph J; Powles, Thomas; Van Herpen, Carla M L; Courtney, Kevin D; Dreicer, Robert; Sudhagoni, Ramu; Schwickart, Martin; Andrianova, Svetlana; Agarwal, Neeraj

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

通过p300/CBP降解靶向组蛋白H2B乙酰化增强子在前列腺癌中的应用

Jie Luo # ,Zhixiang Chen # ,Yuanyuan Qiao # ,Jean Ching-Yi Tien ,Eleanor Young ,Rahul Mannan ,Somnath Mahapatra ,Rupam Bhattacharyya ,Lanbo Xiao ,Tongchen He ,Sanjana Eyunni ,Yuping Zhang ,Yang Zheng ,Fengyun Su ,Xuhong Cao ,Rui Wang ,Yunhui Cheng ,Rithvik Seri ,James George ,Miriam Shahine ,Stephanie J Miner ,Matthew G Rees ,Melissa M Ronan ,Jennifer A Roth ,Ulka Vaishampayan ,Mi Wang ,Shaomeng Wang ,Abhijit Parolia ,Arul M Chinnaiyan

The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade

UBA1-STUB1轴介导癌症免疫逃逸和对检查点阻断的耐药性

Yi Bao ,Gabriel Cruz ,Yuping Zhang ,Yuanyuan Qiao ,Rahul Mannan ,Jing Hu ,Fan Yang ,Mahnoor Gondal ,Miriam Shahine ,Sarah Kang ,Somnath Mahapatra ,Alec Chu ,Jae Eun Choi ,Jiali Yu ,Heng Lin ,Stephanie J Miner ,Dan R Robinson ,Yi-Mi Wu ,Yang Zheng ,Xuhong Cao ,Fengyun Su ,Rui Wang ,Noshad Hosseini ,Marcin Cieslik ,Ilona Kryczek ,Ulka Vaishampayan ,Weiping Zou ,Arul M Chinnaiyan

Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial

Nemvaleukin alfa 单药治疗晚期黑色素瘤和肾细胞癌患者:来自 ARTISTRY-1 1/2 期非随机试验的结果

Calvo, Emiliano; Boni, Valentina; Dumas, Olivier; Shin, Sang Joon; Rosen, Seth D; Chaudhry, Arvind; Debruyne, Philip R; He, Xiaomin; Vaishampayan, Ulka N; McDermott, David F

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

格达托利西布联合帕博西尼和来曲唑治疗既往未接受过全身治疗的激素受体阳性、HER2阴性晚期乳腺癌患者

Wesolowski, Robert; Rugo, Hope S; Specht, Jennifer M; Han, Hyo S; Kabos, Peter; Vaishampayan, Ulka; Wander, Seth A; Gogineni, Keerthi; Spira, Alexander; Schott, Anne F; Abu-Khalaf, Maysa; Mutka, Sarah C; Suzuki, Samuel; Sullivan, Brian; Gorbatchevsky, Igor; Layman, Rachel M

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

一项评估 telaglenastat (CB-839) 联合 nivolumab 治疗转移性黑色素瘤、肾细胞癌和非小细胞肺癌患者的安全性和有效性的 I/II 期研究

Gouda, M A; Voss, M H; Tawbi, H; Gordon, M; Tykodi, S S; Lam, E T; Vaishampayan, U; Tannir, N M; Chaves, J; Nikolinakos, P; Fan, A; Lee, R; McDermott, D; Shapiro, G I; Gandhi, L; Bhatia, S; Katragadda, V; Meric-Bernstam, F

Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma

转移性透明细胞肾细胞癌中15基因预后特征的验证

Monda, Steven M; Nallandhighal, Srinivas; Vaishampayan, Ulka; Singhal, Udit; Knuth, Zayne; Mehra, Rohit; Kaffenberger, Samuel; Hafez, Khaled; Udager, Aaron M; Palapattu, Ganesh S; Morgan, Todd M; Salami, Simpa S